Jayson Rieger - 22 Nov 2024 Form 4 Insider Report for Verrica Pharmaceuticals Inc. (VRCA)

Role: CEO and President, Director
Signature: /s/ Christopher Hayes, Attorney-in-Fact
Issuer symbol: VRCA
Transactions as of: 22 Nov 2024
Net transactions value: $0
Form type: 4
Filing time: 26 Nov 2024, 16:15:13 UTC
Previous filing: 06 Nov 2024
Next filing: 18 Mar 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	VRCA	Common Stock	Purchase		+280,898	+51%		832,826	22 Nov 2024	Direct	F1
transaction	VRCA	Common Stock	Gift	$0	+50,000	+6%	$0.000000	882,826	26 Nov 2024	Direct
holding	VRCA	Common Stock						150	22 Nov 2024	By child
holding	VRCA	Common Stock						2,302	22 Nov 2024	By trust	F2
holding	VRCA	Common Stock						2,301	22 Nov 2024	By trust	F2
holding	VRCA	Common Stock						2,302	22 Nov 2024	By trust	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	VRCA	Series A Warrants (right to buy)	Purchase		+140,449			140,449	22 Nov 2024	Common Stock	140,449	$1.07	Direct	F1
transaction	VRCA	Series B Warrants (right to buy)	Purchase		+140,449			140,449	22 Nov 2024	Common Stock	140,449	$1.34	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The reported securities are included within 280,898 investment units purchased by the Reporting Person for $0.89 per investment unit. Each investment unit consists of one share of Common Stock, a Series A warrant for one half of a share of common stock and a Series B warrant for one half of a share of common stock. The Reporting Person will not be entitled to exercise any portion of a Series A or Series B Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares beneficially owned by the Reporting Person to exceed 9.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise.
F2	These shares are held in separate trusts for the benefit of the Reporting Person's immediate family members. The Reporting Person is a co-trustee of each trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Content

The reported securities are included within 280,898 investment units purchased by the Reporting Person for $0.89 per investment unit. Each investment unit consists of one share of Common Stock, a Series A warrant for one half of a share of common stock and a Series B warrant for one half of a share of common stock. The Reporting Person will not be entitled to exercise any portion of a Series A or Series B Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares beneficially owned by the Reporting Person to exceed 9.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise.

These shares are held in separate trusts for the benefit of the Reporting Person's immediate family members. The Reporting Person is a co-trustee of each trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.